Search PubMedSearch

Biomedical subjects

M Loos

Publications and source records attributed to M Loos.

At least 91 records · Page 5Linked to original sources

Purification and characterization of human, guinea pig and mouse C1q by fast protein liquid chromatography (FPLC).

A simple and rapid procedure for the purification of C1q from human, guinea pig and mouse serum is described. This procedure allows the purification of C1q within one and a half days using euglobulin precipitation, chromatography on Superose 6B, followed by chromatography on Mono S by Fast Protein Liquid Chromatography (FPLC). The highly purified, hemolytically active C1q is free of any immunoglobulins. Since the purification of C1q of three different species was performed by the same purification procedure, a comparison of the subunit compositions was made under reducing and non-reducing conditions on SDS-PAGE. The yield was found to be more than 50%.

Animals

Immunohistological differential diagnosis of inflammatory colonic diseases.

Immunohistological investigations were carried out on human colonic tissue from, I healthy mucosa, 2 slightly inflamed mucosa, 3 mucosa with ulcerative colitis, 4 mucosa with Crohn's colitis, using antibodies against immunoglobulins and complement components. All our antibodies, including F(ab')2 fragments, demonstrated a progressive increase of labelled cells from healthy mucosa through slightly inflamed mucosa to mucosa with ulcerative colitis, in contrast to a complete absence of labelled cells in cases of Crohn's disease. The results are discussed with regard to their pathogenesis and their clinical significance for the differentiation of ulcerative colitis and Crohn's colitis.

Colitis

Electron microscopic study showing antibody-independent binding of C1q, a subcomponent of the first component of complement, to serum-sensitive salmonellae.

Effective serum-mediated killing of sensitive gram-negative bacteria requires all the complement components. In the preimmune phase the antibody-independent interaction of the first component of complement, C1, with the bacteria might be especially important. Electron microscopic studies showed that the C1 subcomponent C1q binds only to the serum-sensitive R form of Salmonella minnesota and not to the serum-resistant S form.

Cell Wall

Characterization of C1q by monoclonal antibodies.

The effect of a purified monoclonal anti-C1q antibody (Ab 242 G3) on the function of C1q, a subcomponent of the first component of complement C1, was studied. No inhibition of purified activated C1 was observed, whereas binding of the Ab to fluid phase C1q, to C1q bound to immune complexes (EAC1q), or to serum C1 in fluid phase resulted in a dose-dependent inhibition of the hemolytic activity of C1. In contrast, when the effect of the Ab on serum C1 bound to immune complexes (EAC1) was measured, no inhibition but a dose-dependent enhancement of the hemolytic activity was obtained. The dose-response curve of the Ab-treated cell bound serum C1 was indistinguishable from that of activated C1. Isolated Fab fragments of this Ab did not cause an increase in C1 activity. After separation of the A, B, and C chains of C1q by SDS-PAGE, Ab 242 G3 reacted in immunoblotting selectively within the C chain. These data indicate that cross-linking of C1q via the C chain of C1q might lead to an internal activation of C1. One out of seven monoclonal antibodies generated against mouse macrophages (M phi was found) to recognize isolated heterologous C1q. This antibody was shown to be cytotoxic and to react in a strain independent way with mouse M phi derived from bone marrow cells as well as with M phi from the peritoneal activity. However, it did not react with mouse granulocytes, thymocytes, T- and B-lymphocytes. The hemolytic activity of fluid phase C1q was inhibited to 50% at a 2 X 10(-4) dilution of hybridoma supernatant, whereas a 100-fold higher concentration was required to inhibit C1q bound to immune complexes (EAC1q) to the same extent. It was demonstrated that this antibody recognizes the isolated globular, Fc-binding portions of the C1q molecule and react with the A and B chains. Since M phi have been shown to synthesize C1q, the Fc-recognizing subcomponent of the first component of complement, evidence was provided that endogenous C1q can serve as an Fc receptor on M phi during secretion. This was demonstrated by a dose-dependent inhibition of Fc receptor activity for EIgG by the F (ab')2 fragment of this monoclonal antibody. In a fluorescence activated cell sorter (FACS) analysis Ab 146 F (ab')2 recognizes up to 75% of unstimulated NMRI peritoneal exudate cells (PEC), 60% and 53% of cells stimulated by thioglycollate and ConA, respectively.(ABSTRACT TRUNCATED AT 400 WORDS)

Animals

Generation of the classical pathway C3 convertase (EAC4b2a) by proteolytic enzymes.

The formation of EAC 4b2a is a two step reaction: first, the temperature- and time-independent binding of C2 to EAC4b2a resulting in EAC4b2 , secondly, the enzymatically triggered conversion of EAC4b2 to EAC4b2a . In the classical cascade of complement activation, the generation of C3 convertase activity is triggered by the C1 esterase, C1-s, which is part of C-1. Evidence is presented that the enzymes trypsin, chymotrypsin, plasmin, and pronase are also able to activate EAC4b2 to EAC4b2a . Kinetic studies showed that the formation of C3 convertase by these enzymes was dependent on concentration, temperature, and time. The optimal conditions were found as follows: trypsin, 2 micrograms/ml (final conc.) for 8 min at 23 degrees C; chymotrypsin 165 micrograms/ml for 18 min at 23 degrees C; plasmin 0.8 units/ml for 15 min at 23 degrees C; pronase 1.25 microgram/ml for 15 min at 23 degrees C. Even under optimal (tmax) conditions the number of generated EAC4b2a differed from enzyme to enzyme: trypsin (= 100%), pronase (58.3%), chymotrypsin (47.9%), and plasmin (12.9%). The enzymes were also able to generate C3 convertase activity from C2 which was adsorbed to EAC1i4b , a C1 inactivator treated and therefore hemolytically inactive intermediate ( EAC1i4b2 ). These findings underline the biological importance of C1 esterase replacing enzymes.

Animals

Antibody-independent killing of gram-negative bacteria via the classical pathway.

It has been recognised since 1895 that some gram-negative bacteria are sensitive towards the lytic action of serum. Many aspects of this phenomenon in regard to antibody-dependent activation of the complement system and the activation of the alternative pathway in the presence and absence of antibodies had been investigated. However, a lot of serum-sensitive bacteria are killed in nonimmune sera and bind directly C1 in the absence of antibodies. Therefore, we were interested in the killing capacity of an antibody-independent activated classical pathway. For the immediate killing of these serum-sensitive bacteria within even one hour, all complement components are essential. The effective bactericidal effect is dependent on the classical pathway components like C1, C4, C2 and Ca2+. C1 is directly bound to the bacteria, becomes activated and is able to cleave C4. For C2-conversion and the further activation of the cascade, an additional serum factor different from an antibody is required. This factor seems to mediate the attachment of C4b to the bacterial surface, which is a prerequisite for the formation of the classical C3-convertase, C4b2a, on the cell surface. The antibody-independent interaction with C1 occurs via C1q, which binds to LPS and possibly also via another C1-subcomponent, C1r and/or C1s. The latter is supposed to interact with outer membrane proteins providing the tight interaction of C1 with the bacteria. This mechanism might be of importance for the killing of R-forms of gram-negative bacteria.

Animals

Activation of the first component of complement, C1, by a monoclonal antibody recognizing the C chain of C1q.

The effect of a purified monoclonal anti-C1q anti-body (Ab 242 G3) on the function of C1q, a subcomponent of the first component of complement C1, was studied. No inhibition of purified activated C1 was observed, whereas binding of the Ab to fluid phase C1q, to C1q bound to immune complexes (EAC1q), or to serum C1 in fluid phase resulted in a dose-dependent inhibition of the hemolytic activity of C1. In contrast, when the effect of the Ab on serum C1 bound to immune complexes (EAC1) was measured, no inhibition, but a dose-dependent enhancement, of the hemolytic activity was obtained. The dose-response curve of the Ab-treated cell-bound serum C1 was indistinguishable from that of activated C1. Isolated Fab fragments of this Ab did not cause an increase in C1 activity. After separation of the A, B, and C chains of C1q by SDS-PAGE, Ab 242 G3 reacted in immunoblotting selectively with the C chain. These data indicate that cross-linking of C1q via the C chain of C1q might lead to an internal activation of C1.

Animals

Monoclonal anti-mouse macrophage antibodies recognize the globular portions of C1q, a subcomponent of the first component of complement.

One of seven monoclonal antibodies generated against mouse macrophages (M phi) was found to recognize isolated heterologous C1q. This antibody was shown to be cytotoxic and to react in a strain-independent way with mouse M phi derived from bone marrow cells as well as with M phi from the peritoneal cavity; it did not react, however, with mouse granulocytes, thymocytes, or T and B lymphocytes. The hemolytic activity of fluid phase C1q was inhibited to 50% at a 2 X 10(-4) dilution of hybridoma supernatant, whereas a 100-fold higher concentration was required to inhibit C1q bound to immune complexes ( EAC1q ) to the same extent. It was demonstrated that this antibody recognizes the isolated globular, Fc-binding portions of the C1q molecule and reacts with the A and B chains. Because M phi have been shown to synthesize C1q, the Fc-recognizing subcomponent of the first component of complement, evidence was provided that endogeneous C1q can serve as an Fc receptor on M phi during secretion. This fact was demonstrated by a dose-dependent inhibition of Fc-receptor activity for EIgG by the F(ab')2 fragment of this monoclonal antibody. These experiments further support the concept that C1q produced by M phi functions on the surface as an Fc-recognizing molecule before it is released and incorporated into the macromolecular complex of serum C1.

Animals

The role of accessory cells in polyclonal T cell activation. I. Both induction of interleukin 2 production and of interleukin 2 responsiveness by concanavalin A are accessory cell dependent.

Recent studies from other laboratories have shown that concanavalin A (Con A) acts at two separate steps in polyclonal T cell activation: interleukin 2 (IL2) production, and induction of responsiveness to IL2. Using a combination of techniques for the depletion of accessory cells from lymph node T cells, we have investigated which of these steps, if not both, is responsible for the known requirement for accessory cells in the Con A response. It was found that with increasing T cell purification, first the ability is lost to produce sufficient levels of endogenous IL2, whereas induction of IL2 responsiveness can still take place. Further removal of accessory cells however yields a population of resting T cells that cannot be induced by Con A to become IL2-reactive. It was concluded that both IL2 production and induction of reactivity to IL2 are accessory cell-dependent events.

Animals

Purification and physicochemical properties of C1q from guinea-pig serum.

An efficient method is described for the isolation of highly purified, IgG-free and stable guinea-pig serum C1q. The procedure includes the chromatography of EDTA-treated serum (25 mM EDTA) on CM- and DEAE-cellulose followed by gel filtration on ACA 34-Ultrogel whereby ammonium sulfate precipitation was used for concentration. The final product stored in a glycerol containing buffer was purified 700-fold with a yield of approximately 50%. It was judged to be homogeneous by several criteria including SDS-PAGE, analytical ultracentrifugation, gel filtration and immunoprecipitation. The protein has a sedimentation rate of 11.3 S and consists of three distinct polypeptide chains A, B and C with mol. wts of 30,200, 28,200 and 24,000. Amino acid analysis revealed a content of 4.42% hydroxyproline, 1.81% hydroxylysine and 18.7% glycine. In contrast to human serum C1q a very low content of cysteine residues was detected. SDS-PAGE analysis performed in the absence of 2-mercaptoethanol but in the presence of 5-10% SDS revealed clearly that gps-C1q is dissociated in a time-dependent manner into the individual chains.

Amino Acids

Activation of the first component of complement, C1: comparison of the effect of sixteen different enzymes on serum C1.

In this study, the effect of sixteen different enzymes on serum C1 and its subcomponents was investigated. The sixteen enzymes could be divided into three groups. First, enzymes which activate native C1: trypsin (optimal concentration 2.4 x 10(-4) mM); alpha-chymotrypsin (2.3 x 10(3) mM); thrombin (1.0 x 10(-5) mM); plasmin (1.9 x 10(-5) mM); elastase (5.8 x 10(-5) mM); pronase (3.0 x 10(-6) mM). All these enzymes are serine esterase and activate native serum C1 bound to EAC4 at the given concentration within 10 min at 30 degrees C. Furthermore, native C1 inhibited by a pentosanpolysulfoester, Sp54, is unable to undergo the internal activation but can be externally activated by the serine esterases. Second, enzymes which do not activate native C1 but result in a dose and time-dependent loss of C1 activity: collagenase; pepsin; carboxypeptidase B. Third, enzymes which have no effect on C1 and C1: Lysozyme; neuraminidase; beta-galactosidase; L-amino acid oxidase; arginase; streptokinase, and acetylcholinesterase.

Animals

[Clinical findings in children with selective deficiency of Clq, a subunit of the first component of complement].

Recently we diagnosed a new complement defect, namely, selective deficiency of the Clq subcomponent of Cl. This defect was manifested by recurrent skin lesions, bouts of serious infections and membranoproliferative glomerulonephritis [4,5]. Within the past two years, we have diagnosed two new similar cases by paying attention to recurrent skin disease and associated symptomatology [7]. These patients had a bad prognosis due to severe bacterial infections and chronic kidney disease. In addition, discovery of new cases should be of help in explaining the importance of complement for host-parasite interactions and whether it is important for their management that an underlying deficiency of Clq be detected in similar cases. It is the purpose of this report to analyze common clinical findings and symptomatology in patients with selective complete Clq deficiency [4-7] and to compare them with other reported cases of Clq defects.

Albuminuria

The functions of endogenous C1q, a subcomponent of the first component of complement, as a receptor on the membrane of macrophages.

C1q, the Fc-recognizing subcomponent of the first component of complement is synthesized by peritoneal macrophages. During the secretion phase C1q serves as an Fc-binding protein in the membrane of macrophages. The Fc-mediated rosette formation was inhibited in a dose-dependent manner when macrophages were pretreated with anti-C1q F(ab')2, whereas C3b rosette formation was not affected. Furthermore, preincubation of peritoneal macrophages with anti-C1q F(ab')2 abolished, dose- and time-dependently, the polyanion-mediated stimulation of secretion of lysosomal enzymes. Polyanion-induced enzyme release was prevented after incubation of polyanions with highly purified C1q. The inhibition of Fc receptor activity by polyanions (i.e. dextran sulfate, liquoid, polyvinyl sulfate) is completely reversed upon treatment of these macrophages with protamine. These findings are compatible with the hypothesis that C1q produced by macrophages serves in the macrophage membrane as an endogenous receptor for Fc and polyanionic molecules. Thus, C1q mediates cell-bound biological receptor functions before it is released from these cells and is incorporated into the macromolecular C1 complex.

Animals

Requirement for an additional serum factor essential for the antibody-independent activation of the classical complement sequence by Gram-negative bacteria.

Killing of Salmonella minnesota and Salmonella typhimurium S and R strains in serum of nonimmune humans and guinea pigs was drastically reduced in the selective absence of C1q, C1r, Ca2+, C4, or C2, the components of the classical complement pathway. Binding of C1 and C1q to the S form and six different core-deficient R mutant strains became stronger the shorter the lipopolysaccharide molecule. C1 and C1q had, under physiological conditions, no affinity to the serum-resistant S forms, whereas these components were bound by the serum-sensitive R forms with high affinity. However, a mixture of the individual complement components C1-C9, which rapidly lysed sensitized erythrocytes, did not kill the serum-sensitive bacteria. Isolated C1 bound to these bacteria cleaved fluid-phase C4 but did not convert C2. C2 turnover could be detected only when serum was used as a source of C1 or C4, indicating that an additional serum component is necessary for the antibody-independent bactericidal effect. Functional tests indicated that this factor is a euglobulin which mediates binding of C4 to the bacteria even in the absence of C1 or after treatment with EDTA. Binding of C4 followed by the generation of C4b sites as acceptors for C2 was a prerequisite for the killing of the bacteria. The factor could not be replaced by immunoglobulin G or immunoglobulin M, nor was it blocked by preincubation with anti-immunoglobulin G or anti-immunoglobulin M.

Animals

Conformational changes in C1q after binding to immune complexes: detection of neoantigens with monoclonal antibodies.

The formation of neoantigens within the C1q molecule after the binding of C1r and C1s to C1q and the binding of C1q to immune complexes is described. The neoantigens were detected by different monoclonal anti-C1q antibodies. This immunochemical study supports the hypothesis drawn from functional studies that the activation of the classical C pathway results from conformational changes within the C1q molecule leading to the activation of C1r and subsequently C1s.

Animals